Trial Profile
A phase I study of lenvatinib for unresectable adenoid cystic carcinoma of the salivary gland
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2020
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Adenoid cystic carcinoma; Salivary gland cancer
- Focus Adverse reactions
- 24 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 24 May 2016 New trial record